Successful treatment of pseudophakic cystoid macular edema with intravitreal bevacizumab.

Despite advances in cataract surgery, cystoid macular edema (CME) is one of the most common causes of poor visual outcome following cataract surgery.1 Cystoid macular edema is related to the disruption of the blood–retinal barrier (BRB) and blood–aqueous barrier and the inflammation induced by prostaglandins or other inflammatory mediators. Pseudophakic CME typically takes 6 to 8 weeks to develop after cataract surgery. Since the 1970s, topical nonsteroidal antiinflammatory agents (NSAIDs) have been used preoperatively and postoperatively to prevent and treat CME following cataract surgery, but resistant cases of macular edema are common.2 Treatment with periocular steroids or intravitreal steroids can cause increased intraocular pressure (IOP) and glaucoma. 3 We report a patient with refractory pseudophakic CME after uneventful phacoemulsification who underwent intravitreal bevacizumab (Avastin) treatment.